Live price temporarily unavailable.
Nexalin Technology (NXL) is a Health Care company. Latest news and coverage below.
| FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $144.1K | $1.32M | $110.7K | $168.7K | $301.6K |
| Growth (year over year) | — | +817.2% | −91.6% | +52.3% | +78.8% |
| Gross profit | $122.6K | $958.1K | $85.1K | $132.1K | $240.3K |
| Gross margin | 85.1% | 72.5% | 76.8% | 78.3% | 79.7% |
| Operating income | −$6.02M | −$1.83M | −$5.70M | −$7.75M | −$8.39M |
| Operating margin | −4177.7% | −138.7% | −5143.5% | −4596.1% | −2781.7% |
| Net income | −$6.08M | −$1.70M | −$4.65M | −$7.61M | −$8.22M |
| Net margin | −4218.9% | −128.5% | −4197.6% | −4508.7% | −2725.8% |
| EPS (diluted) | — | −$0.30 | −$0.63 | −$0.83 | −$0.50 |
| Balance sheet | |||||
| Cash and equivalents | $661.8K | $162.7K | $580.2K | $574.5K | $654.8K |
| Total assets | $753.7K | $7.43M | $3.63M | $4.22M | $4.64M |
| Total liabilities | $2.44M | $1.95M | $425.3K | $546.7K | $887.3K |
| Shareholders' equity | −$1.68M | $5.48M | $3.21M | $3.68M | $3.75M |
| Cash flow | |||||
| Operating cash flow | −$1.08M | −$2.22M | −$3.84M | −$3.94M | −$4.96M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $36.0K | $27.2K | $41.0K | $70.6K | $18.1K | — | $14.9K | $12.2K |
| Growth (year over year) | +49.4% | +32.4% | −47.9% | +163.0% | −49.6% | — | −63.5% | −82.8% |
| Gross profit | $23.3K | $19.7K | $27.5K | $47.8K | $14.2K | — | $13.1K | $8.90K |
| Gross margin | 64.8% | 72.4% | 66.9% | 67.6% | 78.2% | — | 87.8% | 73.2% |
| Operating income | −$2.51M | −$2.88M | −$2.01M | −$1.62M | −$2.35M | — | −$2.12M | −$2.25M |
| Operating margin | −6962.1% | −10579.5% | −4903.6% | −2296.2% | −12924.3% | — | −14179.9% | −18479.7% |
| Net income | −$2.45M | −$2.83M | −$1.99M | −$1.58M | −$2.28M | — | −$2.10M | −$2.24M |
| Net margin | −6794.9% | −10424.5% | −4847.8% | −2239.7% | −12542.3% | — | −14025.7% | −18412.7% |
| EPS (diluted) | −$0.23 | −$0.29 | −$0.15 | −$0.10 | −$0.13 | — | −$0.11 | −$0.11 |
| Balance sheet | ||||||||
| Cash and equivalents | $81.4K | $574.5K | $622.0K | $431.3K | $590.1K | $654.8K | $1.21M | $1.00M |
| Total assets | $5.26M | $4.22M | $2.90M | $6.56M | $5.13M | $4.64M | $3.69M | $3.00M |
| Total liabilities | $299.4K | $546.7K | $574.7K | $600.6K | $357.5K | $887.3K | $808.4K | $1.48M |
| Shareholders' equity | $4.96M | $3.68M | $2.33M | $5.96M | $4.77M | $3.75M | $2.89M | $1.52M |
| Cash flow | ||||||||
| Operating cash flow | −$800.2K | −$1.13M | −$1.43M | −$917.2K | −$1.47M | — | −$1.71M | −$1.80M |
From Nexalin Technology's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Nexalin Technology in our feed yet.